End-organ Damage Clinical Trial
Official title:
A Multi-center, Randomized and Controlled Phase IV Study on the Efficacy and Safety of Two Dose Adjustment Regimens of Nicardipine Injection for Hypertensive Emergency
Verified date | November 2015 |
Source | Astellas Pharma Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Interventional |
To compare the efficacy and safety of two dose adjustment regimens (i.e. weight-based and non-weight-based) for the treatment of Chinese hypertensive emergency patients.
Status | Completed |
Enrollment | 163 |
Est. completion date | January 2014 |
Est. primary completion date | January 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Systolic blood pressure (SBP) =180mmHg and/or diastolic blood pressure (DBP) =120mmHg, and with the evidences or manifestations of end-organ damage (i.e. with any following hypertension emergency symptom: Chest pain, short breath, upper abdominal discomfort, syncope, vertigo, blurred vision, consciousness, hematuria or ischemic change under 12-lead ECG) - Able to and voluntary to complete this study according to this study protocol, and sign the Informed Consent Form by himself/herself (or via his/her legal guardian) Exclusion Criteria: - Allergy to the Nicardipine Injection or its compositions - Serious aortic valve stenosis - Peri-operative hypertension - Cerebral hemorrhage caused by the cerebrovascular malformation, hemangioma or cerebral infarction, cerebral hemorrhage into cerebral ventricle, and cerebral trauma with concomitant cerebral hemorrhage - Other possible influencing factors for the safety or efficacy judgment in the investigators' opinions |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Astellas Pharma China, Inc. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients with target BP | The target BP value is defined by investigators for every subject according to different illness state | After 60 minutes of the treatment | No |
Secondary | Blood pressure after the 6 hour treatment | At 6 hours | No | |
Secondary | The time to get target BP | The target BP value is defined by investigators for every subject according to different illness state | Within 2 hours after treatment | No |
Secondary | Safety assessed by the incidence of adverse events, vital signs and labo tests | For 6 hours | No |